Ward Michael M, Deodhar Atul, Akl Elie A, Lui Andrew, Ermann Joerg, Gensler Lianne S, Smith Judith A, Borenstein David, Hiratzka Jayme, Weiss Pamela F, Inman Robert D, Majithia Vikas, Haroon Nigil, Maksymowych Walter P, Joyce Janet, Clark Bruce M, Colbert Robert A, Figgie Mark P, Hallegua David S, Prete Pamela E, Rosenbaum James T, Stebulis Judith A, Van Den Bosch Filip, Yu David T Y, Miller Amy S, Reveille John D, Caplan Liron
National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland.
Oregon Health & Science University, Portland.
Arthritis Care Res (Hoboken). 2016 Feb;68(2):151-66. doi: 10.1002/acr.22708. Epub 2015 Sep 24.
To provide evidence-based recommendations for the treatment of patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (SpA).
A core group led the development of the recommendations, starting with the treatment questions. A literature review group conducted systematic literature reviews of studies that addressed 57 specific treatment questions, based on searches conducted in OVID Medline (1946-2014), PubMed (1966-2014), and the Cochrane Library. We assessed the quality of evidence using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. A separate voting group reviewed the evidence and voted on recommendations for each question using the GRADE framework.
In patients with active AS, the strong recommendations included use of nonsteroidal antiinflammatory drugs (NSAIDs), use of tumor necrosis factor inhibitors (TNFi) when activity persists despite NSAID treatment, not to use systemic glucocorticoids, use of physical therapy, and use of hip arthroplasty for patients with advanced hip arthritis. Among the conditional recommendations was that no particular TNFi was preferred except in patients with concomitant inflammatory bowel disease or recurrent iritis, in whom TNFi monoclonal antibodies should be used. In patients with active nonradiographic axial SpA despite treatment with NSAIDs, we conditionally recommend treatment with TNFi. Other recommendations for patients with nonradiographic axial SpA were based on indirect evidence and were the same as for patients with AS.
These recommendations provide guidance for the management of common clinical questions in AS and nonradiographic axial SpA. Additional research on optimal medication management over time, disease monitoring, and preventive care is needed to help establish best practices in these areas.
为强直性脊柱炎(AS)和非放射学中轴型脊柱关节炎(SpA)患者的治疗提供循证建议。
一个核心小组从治疗问题入手,牵头制定这些建议。一个文献综述小组基于在OVID Medline(1946 - 2014年)、PubMed(1966 - 2014年)和考克兰图书馆进行的检索,对涉及57个具体治疗问题的研究进行系统的文献综述。我们使用推荐分级、评估、制定与评价(GRADE)方法评估证据质量。一个独立的投票小组审查证据,并使用GRADE框架就每个问题的建议进行投票。
在活动性AS患者中,强烈推荐包括使用非甾体抗炎药(NSAIDs);若尽管使用NSAIDs治疗但活动仍持续,则使用肿瘤坏死因子抑制剂(TNFi);不使用全身性糖皮质激素;使用物理治疗;对于晚期髋关节炎患者使用髋关节置换术。有条件推荐包括:除伴有炎症性肠病或复发性虹膜炎的患者应使用TNFi单克隆抗体外,没有哪种特定的TNFi更具优势。对于尽管使用NSAIDs治疗但仍有活动性非放射学中轴型SpA的患者,我们有条件地推荐使用TNFi治疗。对于非放射学中轴型SpA患者的其他建议基于间接证据,与AS患者相同。
这些建议为AS和非放射学中轴型SpA常见临床问题的管理提供了指导。需要随着时间推移对最佳药物管理、疾病监测和预防保健进行更多研究,以帮助确立这些领域的最佳实践。